Efficacy of Clobetasol Vs Intralesional Triamcinolone in Lichen Planus Treatment

Summary

The purpose of this study is to compare the efficacy and safety of two standard corticosteroid treatments for hypertrophic lichen planus (HLP), a chronic inflammatory skin condition that causes thick, intensely itchy plaques. Patients participating in the study will be randomly assigned to one of two treatment groups: * Group A will apply a superpotent topical steroid cream (Clobetasol propionate 0.05%) to their lesions twice daily for 12 weeks. * Group B will receive intralesional injections of a steroid medication (Triamcinolone acetonide 10 mg/mL) directly into the lesions once every 4 weeks for a total of four sessions over 12 weeks. The primary objective is to determine which approach achieves a better reduction in plaque thickness and severity using the Lichen Planus Severity Index (LPSI) score at week 12. The study will also track changes in itching severity using a Visual Analog Scale (VAS), changes in overall lesion surface area, and monitor for any local side effects such as skin thinning or pigment changes.

Timeline

Start

2026-10-01

Primary completion

2027-04-01

Completion

2027-04-30

Publications

• Background Clim A, Maranduca MA, Filip N, Tanase DM, Floria M, Pinzariu AC, Popa IP, Nemteanu R, Cozma TC, Faur FI, Serban DN, Scripcariu DV, Serban IL. The Influence of Atorvastatin Treatment on Homocysteine Metabolism and Oxidative Stress in an Experimental Model of Diabetic Rats. Life (Basel). 2024 Nov 2;14(11):1414. doi: 10.3390/life14111414.
• Background Sado M, Shirahase J, Yoshimura K, Miura Y, Yamamoto K, Tabuchi H, Kato M, Mimura M. Predictors of repeated sick leave in the workplace because of mental disorders. Neuropsychiatr Dis Treat. 2014 Jan 29;10:193-200. doi: 10.2147/NDT.S55490. eCollection 2014.
• Background Guo L, Zhang H, Liu P, Mi T, Ha D, Su L, Huang L, Shi Y, Zhang J. Preclinical Assessment of Paclitaxel- and Trastuzumab-Delivering Magnetic Nanoparticles Fe3O4 for Treatment and Imaging of HER2-Positive Breast Cancer. Front Med (Lausanne). 2021 Oct 28;8:738775. doi: 10.3389/fmed.2021.738775. eCollection 2021.

Drugs

Indications